Company / Cash & Equivalents
Catalyst Pharmaceuticals Partners, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$709.2M
FY2025
5-year range
$137.6M / $709.2M
FY2021-FY2025
Trend
+37.0%
vs FY2024
Sector context
#29 of 206
Health Care
What the data says
Catalyst Pharmaceuticals Partners, Inc.'s cash & equivalents of $709M is higher than 86% of companies in the Health Care sector (FY2025). Improved from $138M to $709M over the past 2 years.
Based on SEC 10-K filings.
$709M in FY2025 with a 5-year CAGR of +40.3%. Top quartile in the Health Care sector.
Improved from $138M to $709M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +33.5%
- 5-Year CAGR
- +40.3%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 206This company $709.2M Sector average $672.3M
▼
+5.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +40.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 37.0% year-over-year.
- Ranks #29 out of 206 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $709.2M | +37.0% |
| FY2024 | $517.6M | +276.0% |
| FY2023 | $137.6M | -53.9% |
| FY2022 | $298.4M | +74.0% |
| FY2021 | $171.4M | +31.6% |
| FY2020 | $130.2M | +45.5% |
| FY2019 | $89.5M | +440.6% |
| FY2018 | $16.6M | +19.2% |
| FY2017 | $13.9M | +0.0% |
| FY2016 | $13.9M | -50.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026